priors.science/reviews/targeted-therapy-breast-cancer

Targeted Therapy Breast Cancer

The current evidence on 8 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

8claims tracked
156primary papers reviewed
10 Aug 2026latest evidence review
Weeklyre-scored against new papers
4 Established · 4 Likely · 0 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Olaparib or talazoparib in BRCA-mutant breast cancerBrca DnaEstablished89%20
Abemaciclib adjuvant therapy in early breast cancerCdk46Established87%19
Capivasertib (AKT inhibitor) in hormone receptor-positive metastatic breast cancerPi3k AktEstablished86%21
Pembrolizumab neoadjuvant therapy in triple-negative breast cancerIci BCEstablished85%20
CDK4/6 inhibitors plus endocrine therapy in hormone receptor-positive, HER2-negative metastatic breast cancerCdk46Likely84%25
Alpelisib in PIK3CA-mutant hormone receptor-positive metastatic breast cancerPi3k AktLong-standingLikely84%19
Sacituzumab in third-line triple-negative breast cancerBrca DnaLikely83%20
Pembrolizumab in PD-L1-positive metastatic triple-negative breast cancerIci BCLong-standingLikely81%18
Track Targeted Therapy Breast Cancer.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.
Where the evidence sits in time
Long-standingMost of this evidence is older than the rest of this field.